ESLA Company Profile and Key Details

ESLA has shown weak momentum, losing -14.06% over the past week and -47.94% over the past quarter, though year-to-date performance is down -41.6%. Short-term trend indicators are bullishly aligned (SMA20 -2.36%, SMA50 -5.78%, SMA200 -7.86%). The stock’s 14-day RSI is 47.55 (neutral), while the ATR of 0.16 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -61.9% below its high and over 64.36% above its low. Average 10-day trading volume of 76.33 thousand shares is below the 3-month average of 178.59 thousand, indicating normal recent market interest.

Estrella Immunopharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.04. This means the shares are trading above this model’s fair value.

Estrella Immunopharma, Inc. has 37.07 million shares outstanding. The public float is 10.99 million shares, elevated short interest at 1.61% of float. This equals 162.26 thousand shares. The short ratio is 9.22 days. Institutional investors hold 5.78% of the float. Insiders own 70.36%.

Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $16.00 to $8.00. The high target offers 1532.65% upside. The low target suggests 716.33% downside. The mean target is $12.80. This offers 1206.12% upside. Estrella Immunopharma, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by -30.29%. The prior quarter beat by 114.29%. Over the last six quarters, Apple has recorded several small beats. These include -76.14% in February 15, 2025.

Estrella Immunopharma, Inc. (NASDAQ:ESLA) closed at $0.98 USD, gaining $0.01 (0.54%) from the previous close of $0.97. The stock is currently mid-range between its 52-week high and low $0.73 and $3.15. With a market capitalization of about $41.82 million, Estrella Immunopharma, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.53). Key stats such as the average daily volume over the past year has been around 177.32 thousand shares, volume is running light vs its 52-week average. Headquartered in EmeryVille, CA, Estrella Immunopharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States.

Estrella Immunopharma, Inc. trades at a P/E ratio of -3.02, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -3.81 indicating negative book value, which may reflect financial stress. The P/FCF stands at -24.85, also below market averages.

Our AI price prediction model suggests that Estrella Immunopharma, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.06%, with price expected at $0.96 by April 07, 2026, within a range of $0.85 to $1.07 3-Month Outlook: Projected fall of -67.35%, reaching $0.32 by June 22, 2026, with a range of $0.19 to $0.36. 1-Year Outlook: Projected gain of 126.48%, with price at $2.22 by March 24, 2027, within a range of $0.30 to $2.02.

Estrella Immunopharma, Inc. (NASDAQ:ESLA) shares are down -41.6% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Estrella Immunopharma, Inc. trading at a premium to the broader market with a P/E of -3.02. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $13.71, suggesting 1298.69% upside. Our AI forecast model points to short-term weakness (-2.06% over two weeks), a medium-term fall (-67.35% over three months), and a longer-term gain (126.48% over one year), with expected trading ranges indicating moderate volatility.